Get the Stockscreener App
10.95
0.37%
0.04
After Hours:
10.55
-0.40
-3.65%
Mink Therapeutics Inc stock is traded at $10.95, with a volume of 3,951.
It is up +0.37% in the last 24 hours and down -0.64% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$10.91
Open:
$10.92
24h Volume:
3,951
Relative Volume:
0.32
Market Cap:
$51.40M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-3.6084
EPS:
-3.0346
Net Cash Flow:
$-5.58M
1W Performance:
-0.73%
1M Performance:
-0.64%
6M Performance:
-26.01%
1Y Performance:
+34.36%
1-Day Range:
$10.53
$10.95
1-Week Range:
$10.53
$11.48
52-Week Range:
$6.34
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
10.95 | 51.21M | 0 | -12.36M | -5.58M | -3.0346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
MiNK Therapeutics (INKT) director sells 500 shares in open trades - Stock Titan
The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily
INKT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
INKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
INKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
INKT Technical Analysis & ETF Price Forecast - Intellectia AI
Volume Summary: How does MiNK Therapeutics Inc correlate with Nasdaq2025 Biggest Moves & Community Shared Stock Ideas - baoquankhu1.vn
Precision Trading with Mink Therapeutics Inc. (INKT) Risk Zones - Stock Traders Daily
Published on: 2026-02-18 15:43:58 - baoquankhu1.vn
Downgrade Watch: What are GAN Limiteds technical support levelsEarnings Overview Summary & Growth Focused Entry Reports - baoquankhu1.vn
What is the fair value of MiNK Therapeutics Inc. stock nowQuarterly Trade Summary & Consistent Growth Equity Picks - mfd.ru
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Sectors: Can ZEOWW sustain its profitabilityQuarterly Profit Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Published on: 2026-02-12 21:29:01 - mfd.ru
Can MiNK Therapeutics Inc. maintain its current growth rateJuly 2025 News Drivers & Fast Gain Stock Tips - mfd.ru
Short Covering: Is MiNK Therapeutics Inc a defensive stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
What is MiNK Therapeutics Inc. s revenue forecastTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 1.6%Here's Why - MarketBeat
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 1.6% – Here’s Why - Defense World
Technical Reactions to INKT Trends in Macro Strategies - Stock Traders Daily
MiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia - Nasdaq
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - Investing News Network
MiNK Therapeutics Reports Preclinical Data Showing Anti-Fibrotic Effects of Allo-iNKT Cell Therapy for Idiopathic Pulmonary Fibrosis - geneonline.com
MiNK Therapeutics Presents New Data of allo-iNKT Cell - GlobeNewswire
New IPF lung data: key immune cells depleted in advanced disease - Stock Titan
Published on: 2026-02-03 22:53:59 - baoquankhu1.vn
Trading the Move, Not the Narrative: (INKT) Edition - Stock Traders Daily
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to “Hold” - Defense World
Gains Recap: Is Orfa Corp America Preferred Security a stock for growth or value investorsJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to "Hold" - MarketBeat
(INKT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Decliners Report: Can MiNK Therapeutics Inc maintain its current growth rate2025 Biggest Moves & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Wall Street Recap: Is MiNK Therapeutics Inc forming bullish engulfing patternsWeekly Risk Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
MiNK Therapeutics announces board resignation amid public appointment - MSN
Market Outlook: Why MiNK Therapeutics Inc stock attracts high net worth investorsQuarterly Portfolio Summary & Precise Trade Entry Recommendations - Bộ Nội Vụ
MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Why MiNK Therapeutics Inc. stock remains on watchlists2025 Volume Leaders & Safe Entry Point Alerts - Улправда
How MiNK Therapeutics Inc. (6Q40) stock trades under stagflationWeekly Market Report & Consistent Growth Equity Picks - ulpravda.ru
How MiNK Therapeutics Inc. stock valuations compare to rivalsQuarterly Market Summary & Free Verified High Yield Trade Plans - Улправда
Why MiNK Therapeutics Inc. stock attracts global investorsShort Setup & Target Return Focused Stock Picks - Улправда
Can MiNK Therapeutics Inc. (6Q40) stock sustain breakout momentum2025 Geopolitical Influence & Reliable Price Action Trade Plans - Улправда
How MiNK Therapeutics Inc. (6Q40) stock behaves under inflation pressureJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - ulpravda.ru
MiNK Therapeutics to begin phase 1 trial of iNKT cell therapy for GvHD - Investing.com Australia
MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - The Manila Times
MiNK Therapeutics and University of Wisconsin–Madison - GlobeNewswire
MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy to Evaluate Prevention of Graft-Versus-Host Disease - Investing News Network
MiNK Therapeutics announces reverse stock split - MSN
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):